Semzuvolimab

DB18920InvestigationalProtein Based Therapies

Semzuvolimab is under investigation in clinical trial NCT03149211 (To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults).

Mechanism: Pharmacologically active on T-cell surface glycoprotein CD4
Curator reviewed
Also known as: DB4C7 mAb · Mab db4c7
Code names: UB-421 · UB-421 (DB4C7 MAB)

Resolves to

Compound

UNII4180O0RM6KCAS2409099-32-5

Targets

P01730CD4

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

11Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Semzuvolimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account